Royal Philips (NYSE:PHG) announced that it has won FDA 510(k) clearance for a wearable biosensor to help manage confirmed and suspected COVID-19 patients in the hospital.
The Amsterdam-based company described the BX100 biosensor as a wireless wearable sensor designed to help healthcare providers detect when COVID-19 patients in lower-acuity units are at risk for deterioration so they can intervene.
The lightweight, disposable biosensor is a 5-day, single-use wearable patch can be integrated with a scalable hub to monitor multiple patients across different rooms, according to Philips. It is designed to adhere discreetly to the chest to collect, store, measure and transmit respiratory rate and heart rate every minute — the top two predictors of deterioration — as well as contextual parameters such as posture, activity level and ambulation. The sensor is built to work with existing …